Disease Areas

Inflammatory bowel disease

Sleeve gastrectomy may be safer than gastric bypass for IBD patients (28/2/2019) ›Azathioprine ups pancreatitis risk in pediatric IBD (31/1/2019) ›Postpartum substance abuse, mood disorders more common with IBD (25/1/2019) ›Advanced endoscopic techniques improve IBD assessment (8/1/2019) ›Cancer risk in IBD associated with age and recent immunomodulator use (19/9/2018) ›Clinical effect of vedolizumab on articular manifestations spondyloarthritis associated with IBD (16/6/2018) ›Quiescent disease, characteristics and biomarker correlations (20/2/2018) ›Significant reduction of emergency stoma surgeries for CD (17/2/2018) ›Genetic predisposition for gut barrier dysfunction (17/2/2018) ›ILC1 distribution predicts response to ustekinumab (17/2/2018) ›Integration of “omics” and potential for clinical practice (17/2/2018) ›Targeting early disease: lessons from rheumatoid arthritis (17/2/2018) ›Higher rates of remission and healing with vedolizumab vs. TNF antagonist (17/2/2018) ›Combining new drugs with different mechanisms (17/2/2018) ›Vedolizumab in anti-TNF-naïve IBD patients and safety profile (17/2/2018) ›Higher colectomy rate with infliximab vs. conventional therapies in more severe UC (17/2/2018) ›Central role of IL-23 in molecular resistance to anti-TNF therapy (17/2/2018) ›Shallow whole-genome sequencing predicts future cancer risk of LGD in UC (17/2/2018) ›Long-term safety profile of adalimumab (17/2/2018) ›SLC12A2 potential marker of dysplasia associated to inflammation in UC (17/2/2018) ›Long-term risk of advanced neoplasia after colonic low-grade dysplasia in IBD (17/2/2018) ›Enhanced post-operative recovery pathways for IBD patients (17/2/2018) ›Significantly increased risk of CRC and/or HGD after appendectomy in UC (17/2/2018) ›Malignancies occur infrequently with tofacitinib (17/2/2018) ›Diagnostic techniques for IBD: the ECCO-ESGAR Guidelines (17/2/2018) ›Overall manageable safety profile of tofacitinib in long-term use (17/2/2018) ›

Lung cancer

Electromagnetic navigation: an instant hit? (11/4/2019) ›Comprehensive profiling in localised stage lung cancer (11/4/2019) ›Immunotherapy in elderly: diverse findings across the globe (11/4/2019) ›Post-study immunotherapy confounds primary survival outcome (11/4/2019) ›Survival benefit persists despite post-discontinuation therapy (11/4/2019) ›Next-generation sequencing assay detects genetic variants driving cancer, resistance in NSCLC (2/4/2019) ›Pembrolizumab may help some with advanced non-small-cell lung cancer (2/4/2019) ›Cranial irradiation doesn't boost survival in locally advanced lung cancer (26/3/2019) ›Lung-cancer screens effective in asbestos-exposed smokers (14/3/2019) ›Liquid biopsy on par with tissue testing in advanced lung cancer (5/3/2019) ›Stereotactic ablative radiotherapy tops for inoperable early non-small-cell lung cancer (21/2/2019) ›It's never too late to quit smoking before lung surgery (16/1/2019) ›Lung cancer screening complications may be higher than expected (14/1/2019) ›No progression-free survival benefit with nintedanib plus pemetrexed/cisplatin for malignant pleural mesothelioma of epithelial subtype (26/9/2018) ›Small-cell lung cancer circulating tumour cell derived explants (26/9/2018) ›Effects of dose modifications on safety and efficacy of dacomitinib for EGFR-mutant non-small-cell lung cancer (26/9/2018) ›Central nervous system activity of ramucirumab + osimertinib in patients with advanced T790M-positive EGFR-mutant non-small-cell lung cancer (26/9/2018) ›Prognostic value of distant organ-specific metastases in newly diagnosed lung neuroendocrine tumours (26/9/2018) ›Interview with IASCL President (26/9/2018) ›Entrectinib treatment in patients with ROS1+ NSCLC (26/9/2018) ›Angiogenic and stromal biomarkers in malignant mesothelioma (26/9/2018) ›Patient-reported outcomes of first-line nivolumab + ipilimumab in high tumour mutational burden advanced non-small-cell lung cancer (26/9/2018) ›Osimertinib and RET inhibitor BLU-667 in an EGFR-mutant patient with acquired RET rearrangement (26/9/2018) ›Accumulation of concomitant mutations involved in drug resistance in sequential ALK TKI treatments of ALK-positive NSCLC (26/9/2018) ›Avelumab vs docetaxel for previously treated advanced non-small-cell lung cancer (26/9/2018) ›Next generation immunotherapy in non-small-cell lung cancer (26/9/2018) ›Choice of taxane and addition of pembrolizumab for metastatic squamous non-small-cell lung cancer (26/9/2018) ›Combination therapies: Where are we in 2018? (26/9/2018) ›Unmet needs in surgical management of malignant pleural mesothelioma (26/9/2018) ›PD-L1 expression in untreated EGFR-mutant non-small-cell lung cancer and response to osimertinib (26/9/2018) ›Crizotinib-treated ALK IHC-positive advanced NSCLC is associated with an unfavourable prognosis when FISH negative (26/9/2018) ›Benefits of chest CT screening (26/9/2018) ›New standard of care in extensive-stage small-cell lung cancer (26/9/2018) ›Potential for brigatinib as a first-line treatment option for ALK+ non-small-cell lung cancer (26/9/2018) ›Durvalumab after chemoradiotherapy extends OS in stage 3, unresectable non-small-cell lung cancer (26/9/2018) ›Spread through air spaces is prognostic in lung neuroendocrine tumours (26/9/2018) ›

Subscribe for free ›

Stay up-to-date with Medicom. Subscribe to the Medicom Conference Reports and newsletter.

"The Medicom Conference Reports offer an excellent summary of the most important developments and presentations in medicine. They are well written and include the most recent references. Very informative and highly recommended."

Editor Medicom Conference Report series in Pulmonology

  • Prof dr P.N. Richard Dekhuijzen,
  • MD, PhD
  • Radboud university medical center
  • Dept. of Pulmonary Diseases

About us ›

Medicom provides the highest quality medical information and tools to international medical professionals.